Japan Academia Progresses Novel Melanoma Drug Despite Pharma 'Reluctance'
Promising Phase II Results
Academia-developed novel oral PAI-1 inhibitor in combination with Opdivo showed a strong response rate in PD-1 treated melanoma patients with certain disease characteristics and could represent a new breakthrough for a class with no clinical stage competitors.
